CenterWatch, a leading publisher of clinical trials information for patients and professionals, announced today that it has launched a revamped version of its award-winning Clinical Trials Listing Service (CTLS) to better serve the public and patient communities.
CenterWatch
, a leading publisher of clinical trials information for patients and professionals, announced today that it has launched a revamped version of its award-winning
Clinical Trials Listing Service
(CTLS) to better serve the public and patient communities.
The new CTLS™ presents the largest international listing of phase I – IV clinical trials actively recruiting volunteers in simpler language, improved format, more advanced search capabilities and better navigation. CenterWatch solicited extensive feedback from patients to guide and direct the revamp effort.
“Patients and their advocates have long complained that online clinical trial registries and listings are too technical, difficult to understand and of questionable quality,” said Niki Eastley, CenterWatch’s senior manager of Internet Operations and Development. “We’re so pleased to make these enhancements with the patient at the center of our revamp efforts.”
As an independent publisher, CenterWatch’s clinical trial listing service aggregates information from a variety of sources including directly from research sponsors and from investigative sites making the CTLS™ the largest and most comprehensive listing of industry-funded clinical trials on the web today.
“We apply our editorial and quality standards to the listings in the CenterWatch service,” said Joan Chambers, Chief Operating Officer. “Most web sites show a small number of trials of variable quality. The CTLS™ is the go-to destination by patients and their advocates for the largest, highest quality, easiest-to-use clinical trial information available.”
Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Managing Side Effects and Dosing in Off-Label GLP-1 Use with Help from Real-World Evidence
July 18th 2025Shipra Patel, global therapeutic area section head, endocrinology, global head, pediatrics, Parexel, explains how real-world data is helping researchers navigate gastrointestinal side effects, dose flexibility, and long-term tolerability in off-label GLP-1 use.
Anselamimab Misses Primary Endpoint in Phase III CARES Trials for AL Amyloidosis
July 17th 2025In the Phase III CARES trials, anselamimab did not meet the primary endpoint for advanced-stage AL amyloidosis, but a prespecified subgroup analysis revealed meaningful improvements in survival and cardiovascular outcomes.